Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;39(2):289-296.
doi: 10.1111/jgh.16411. Epub 2023 Nov 14.

A pharmacovigilance study of association between proton-pump inhibitors and rhabdomyolysis event based on FAERS database

Yuxuan Sun  1 , Ailin Zhang  1 , Meiling Zuo  1 , Jingtao Chen  2 , Liqin Zhu  1   3
Affiliations

A pharmacovigilance study of association between proton-pump inhibitors and rhabdomyolysis event based on FAERS database

Yuxuan Sun et al. J Gastroenterol Hepatol. 2024 Feb.

Abstract

Background and aim: The association between proton-pump inhibitors (PPIs) and rhabdomyolysis were unclear. The aim of this study was to explore and systematically analyze the potential link between five PPIs and the rhabdomyolysis events using the FDA Adverse Event Reporting System (FAERS) database.

Methods: Suspected rhabdomyolysis events associated with PPIs were identified by data mining with the reporting odds ratio (ROR), proportional reporting ratio (PRR), the information component (IC), and Empirical Bayes Geometric Mean (EBGM). Demographic information, drug administration, and outcomes of PPI-induced rhabdomyolysis events were also analyzed.

Results: There were 3311 reports associated with PPI-induced rhabdomyolysis that were identified. After removing duplicates, 1899 cases were determined to contain complete patient demographic data. The average age was 65 ± 18 year and 57% were male. Omeprazole and pantoprazole had the same largest percentage of reports. Lansoprazole had the highest ROR index of 12.67, followed by esomeprazole (11.18), omeprazole (10.27), rabeprazole (10.06), and pantoprazole (9.24). PRR, IC, and EBGM showed similar patterns. This suggested that lansoprazole exhibited the strongest correlation with rhabdomyolysis. In rhabdomyolysis events, PPIs were mainly "concomitant" (>60%), and only a few cases were "primary suspects" (<15%). Rabeprazole showed the lowest death rate while lansoprazole showed the highest.

Conclusions: The study suggested that significant rhabdomyolysis signals were associated with PPIs. Further research should be performed in drug safety evaluation for a more comprehensive association.

Keywords: Adverse drug events; Drug safety; Pharmacovigilance; Proton-pump inhibitors; Rhabdomyolysis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Proton Pump Inhibitors. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
    1. Colmenares EW, Pappas AL. Proton pump inhibitors: risk for myopathy? Ann. Pharmacother. 2017; 51: 66-71.
    1. Mitsuboshi S, Hamano H, Kuniki Y et al. Proton pump inhibitors and rhabdomyolysis: analysis of two different cross-sectional databases. Ann. Pharmacother. 2023; 57: 1255-1263.
    1. Duncan SJ, Howden CW. Proton pump inhibitors and risk of rhabdomyolysis. Drug Saf. 2017; 40: 61-64.
    1. Boutaud O, Roberts LJ 2nd. Mechanism-based therapeutic approaches to rhabdomyolysis-induced renal failure. Free Radic. Biol. Med. 2011; 51: 1062-1067.

LinkOut - more resources